Basic Eldepryl Information

• INN (International Nonproprietary Name): Selegiline
• Brand names available in Australia: Eldepryl, Zelapar
• ATC Code: N04BD01
• Forms & dosages: Capsules (5 mg), Orally Disintegrating Tablets (Zelapar)
• Manufacturers in Australia: Sovereign Medical, Somerset Pharmaceuticals
• Registration status in Australia: Prescription only (Rx)
• OTC / Rx classification: Prescription only

Latest Research Highlights

Recent studies have shed light on the efficacy and safety of Eldepryl (selegiline) in treating Parkinson’s disease. Between 2022 and 2025, both Australian and international clinical trials provided robust data regarding its benefits and risks. A meta-analysis covered multiple trials examining patient outcomes compared to placebo and other treatments. Eldepryl has shown significant efficacy in improving motor symptoms of Parkinson’s disease, particularly when used as an adjunct therapy with levodopa. Research indicated that patients experienced meaningful improvements in their quality of life without a heavy burden of adverse events. The table below summarises key findings from recent trials:

Clinical Trial	Efficacy Outcomes	Adverse Event Frequencies	Long-term Effectiveness
Trial 1	30% improvement in motor function	15% nausea, 10% headache	Effective up to 2 years
Trial 2	Significant quality of life enhancement	5% dizziness, 3% orthostatic hypotension	Stable efficacy over 3 years

Adverse events primarily included gastrointestinal issues and headaches, reported at frequencies comparable to placebo. Importantly, the long-term effectiveness suggests that Eldepryl might delay the progression of symptoms and extend the benefits of primary dopaminergic therapies. For professionals managing patients with Parkinson's, the evidence supports Eldepryl as a valuable component of a comprehensive treatment strategy.

Clinical Effectiveness in Australia

The Pharmaceutical Benefits Scheme (PBS) plays a crucial role in determining the accessibility of Eldepryl for Australian patients. Data from the Therapeutic Goods Administration (TGA) indicate that Eldepryl is effective in alleviating motor symptoms associated with Parkinson’s disease. When prescribed as adjunct therapy alongside levodopa, patients have reported enhanced therapeutic outcomes. Statistics reveal that those using Eldepryl alongside their primary medication experienced a reduction in “off” time, amplifying satisfaction levels significantly. A survey conducted among users noted the following:

• 85% reported improved motor function.
• 70% experienced fewer side effects compared to previous treatments.
• High satisfaction with ongoing management under PBS guidelines.

Overall, Eldepryl's PBS coverage ensures that patients have greater access to an effective treatment, crucial for those grappling with the debilitating effects of Parkinson’s disease.

Indications & Expanded Uses

According to TGA guidelines, Eldepryl is primarily indicated for the management of Parkinson's disease, especially in conjunction with levodopa therapy. Additionally, off-label use has become prevalent in Australian clinics for conditions extending beyond Parkinson's, including treatment-resistant depression. Recent clinical settings have identified potential benefits in various neurological conditions, with some practitioners exploring its efficacy further. The indications can be summarised as follows:

• Management of Parkinson's disease symptoms.
• Adjunct therapy with levodopa.
• Off-label use for certain mood disorders.

Patients considering Eldepryl should discuss all possibilities with their healthcare provider to ensure comprehensive care and explore potential off-label benefits while monitoring for side effects.

Composition & Brand Landscape

Eldepryl contains the active ingredient selegiline, a monoamine oxidase B (MAO-B) inhibitor. It's important to recognise the various forms and dosages available for Australian consumers. The available products include:

Brand Name	Active Ingredient	Form & Packaging
Eldepryl	Selegiline	Tablets (5 mg, 10 mg)
Zelapar	Selegiline	Orally Disintegrating Tablets (1.25 mg)

Understanding the landscape of available brands and formulations helps patients make informed choices, especially considering that generics may also be available under PBS listings.

Contraindications & Special Precautions

Before initiating treatment with Eldepryl, it's essential to be aware of both absolute and relative contraindications. Certain populations, particularly the elderly and Indigenous communities, may require careful consideration and monitoring. Absolute contraindications include:

• Known hypersensitivity to selegiline.
• Concurrent use with other MAO inhibitors.
• Pheochromocytoma.

Relative contraindications require extra vigilance, particularly in patients with:

• Cardiovascular diseases.
• History of mental health disorders.
• Increased sensitivity to common side effects.

Daily-life restrictions may be necessary until patients adjust to Eldepryl. For instance, activities such as driving or operating machinery should be approached cautiously when side effects arise. Health professionals should guide patients in understanding these risks to ensure safe medication practices.

FAQ Section

Common questions about Eldepryl (selegiline) often arise among Australian patients. Here’s a rundown of the most frequently asked questions to help ease concerns:

Is Eldepryl available without prescription?

Yes, Eldepryl can be purchased without a prescription at your local pharmacy, but it’s always best to consult with a healthcare professional for advice tailored to individual needs.

What are possible side effects?

Common side effects of Eldepryl include nausea, dry mouth, dizziness, and insomnia. Report any severe reactions to a healthcare provider immediately, especially if they involve agitation or hallucinations.

How should I take Eldepryl?

Typically, Eldepryl is taken once or twice daily, with doses ranging between 5 to 10 mg. If a dose is missed, it should be taken as soon as remembered unless it’s close to the next dose.

Can Eldepryl interact with other medications?

Yes, Eldepryl has interactions with various medications, including other monoamine oxidase inhibitors and certain pain medications, which can lead to serious side effects. Always inform your doctor about all medications you’re taking.

Is there special advice for elderly patients?

Elderly patients may require lower doses due to increased sensitivity to the medication. Careful adjustment and monitoring are recommended.

Guidelines for Proper Use

When dispensing Eldepryl, Australian pharmacists follow specific counselling approaches to ensure patients understand their treatment:

Adherence: Encourage adherence to the prescribed dosing schedule. Patients should be reminded not to double doses if a dose is missed and to take it as soon as they remember.

Consultations: During consultations, patients should discuss any other medications they are taking, health updates, and any side effects experienced while on Eldepryl. This open line fosters better management of their therapy.

Patient Resources: Pharmacists should inform patients about available support resources from the Pharmaceutical Benefits Scheme (PBS) and other national health authorities. These resources provide ongoing management and guidance for patients using Eldepryl.

Common Recommendations:

• Maintain a medication schedule to build routine.
• Use reminder systems if necessary, like alarms or medication management apps.

By focusing on these aspects, pharmacists can significantly enhance patient knowledge and confidence in managing their treatment with Eldepryl, empowering them to take control of their health.

City	Region	Delivery Time
Sydney	New South Wales	5–7 days
Melbourne	Victoria	5–7 days
Brisbane	Queensland	5–7 days
Perth	Western Australia	5–7 days
Adelaide	South Australia	5–7 days
Hobart	Tasmania	5–9 days
Canberra	Australian Capital Territory	5–7 days
Gold Coast	Queensland	5–9 days
Newcastle	New South Wales	5–9 days
Wollongong	New South Wales	5–9 days
Geelong	Victoria	5–9 days
Cairns	Queensland	5–9 days